Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
- A new personalized mRNA vaccine for melanoma is being hailed by some oncologists as a major breakthrough after it reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a late-stage clinical trial.
- Robert Vonderheide, director of Penn Medicine’s Abramson Cancer Center and president-elect of the American Association for Cancer Research, said the results are a “game changer.
- ”“It will be seen as the first step toward using cancer vaccines to their full potential,” said Vonderheide, who was not involved in the trial.
Unverified
- A new personalized mRNA vaccine for melanoma is being hailed by some oncologists as a major breakthrough after it reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a late-stage clinical trial.
- Robert Vonderheide, director of Penn Medicine’s Abramson Cancer Center and president-elect of the American Association for Cancer Research, said the results are a “game changer.
- ”“It will be seen as the first step toward using cancer vaccines to their full potential,” said Vonderheide, who was not involved in the trial.
Sources: NBC News